Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Atyr Pharma Inc Cmn (LIFE) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 80,640
  • Shares Outstanding, K 23,720
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,970 K
  • 36-Month Beta 3.36
  • Price/Sales N/A
  • Price/Book 1.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +31.48%
on 11/10/16
3.80 -6.58%
on 11/21/16
+0.85 (+31.48%)
since 11/08/16
3-Month
2.55 +39.22%
on 11/04/16
3.80 -6.58%
on 11/21/16
+0.44 (+14.15%)
since 09/08/16
52-Week
2.48 +43.15%
on 06/29/16
10.93 -67.52%
on 12/21/15
-4.53 (-56.06%)
since 12/08/15

Most Recent Stories

More News
aTyr Pharma Enters into $20 Million Credit Facility

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced it has entered into...

aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session

aTyr Pharma Inc. (LIFE) saw its shares rise almost 6% in the last trading session.

aTyr Pharma Announces Third Quarter 2016 Operating Results

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced operating results...

aTyr Pharma to Present at Three Upcoming Conferences in November

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced its participation...

aTyr Pharma Receives FDA Fast Track Designation for Resolaris(TM) to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product...

aTyr Pharma Presents Additional Data for Resolaris(TM) Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society

aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21st International Congress of the World...

Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is...

Life Science Reagents Market to Reach US$25.7 bn by 2020; Use of Biotechnology-based Diagnostic Tools to Provide Lucrative Opportunities, says TMR

The global life science reagents market is fragmented with Sigma Aldrich Corporation, Life Technologies, and GE Healthcare being the top three players. The requirement for high initial capital and stringent...

aTyr Pharma Announces Presentation at the 21st International Annual Congress of the World Muscle Society

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced participation in...

aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research

aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that David J. King, PhD, has joined the company as Senior Vice President, Research. Dr. King will lead aTyr's research and preclinical efforts to advance...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Support & Resistance

2nd Resistance Point 3.75
1st Resistance Point 3.65
Last Price 3.55
1st Support Level 3.40
2nd Support Level 3.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.